Abstract
We report the second pediatric case of New Delhi metallo-β-lactamase-1-producing Enterobacteriaceae in the United States. Laboratory methods included various phenotypic antimicrobial susceptibility testing assays, as well as polymerase chain reaction assays for carbapenemase-encoding genes. Laboratory challenges and the limited number of effective antimicrobial agents and the lack of pediatric-specific safety and efficacy data for these drugs are discussed.
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use*
-
Child
-
Enterobacteriaceae / classification
-
Enterobacteriaceae / drug effects
-
Enterobacteriaceae / enzymology*
-
Enterobacteriaceae / isolation & purification
-
Enterobacteriaceae Infections / drug therapy
-
Enterobacteriaceae Infections / microbiology*
-
Female
-
Fosfomycin / pharmacology
-
Fosfomycin / therapeutic use
-
Humans
-
Microbial Sensitivity Tests
-
Minocycline / analogs & derivatives
-
Minocycline / pharmacology
-
Minocycline / therapeutic use
-
Tigecycline
-
United States
-
beta-Lactam Resistance
-
beta-Lactamases / biosynthesis*
Substances
-
Anti-Bacterial Agents
-
Fosfomycin
-
Tigecycline
-
beta-Lactamases
-
beta-lactamase NDM-1
-
Minocycline